Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Lips

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
Breast Cancer Research : BCR|November 14, 2023
PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learningWitali Aswolinskiy, Enrico Munari, Hugo M Horlings, et al.
British Journal of Cancer|August 19, 2021
Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breastMaartje van Seijen, Esther H Lips, Liping Fu, et al.
NPJ Breast Cancer|May 6, 2026
Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoringS Doyle, M A Oerlemans, J Brunekreef, et al.
British Journal of Cancer|October 24, 2013
Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancerL S Rigter, C E Loo, S C Linn, et al.
Immuno-Oncology Technology|September 10, 2025
Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stagesN A M Bakker, H Garner, V C M Geurts, et al.
The Journal of Pathology|May 29, 2008
High frequency of copy-neutral LOH in MUTYH-associated polyposis carcinomasA Middeldorp, M van Puijenbroek, M Nielsen, et al.
Radiology|November 18, 2025
Cross-National Radiomics Validation Using Mammography to Predict Occult Invasion in Ductal Carcinoma in SituRui Hou, Lars J Grimm, Jeffrey R Marks, et al.
Breast Cancer Research : BCR|June 19, 2023
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancerM C Liefaard, A van der Voort, M S van Ramshorst, et al.
The American Journal of Surgical Pathology|June 18, 2019
Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCISLindy L Visser, Lotte E Elshof, Koen Van de Vijver, et al.
British Journal of Cancer|April 5, 2025
Development of radiomics-based models on mammograms with mass lesions to predict prognostically relevant characteristics of invasive breast cancer in a screening cohortJim Peters, Merle M van Leeuwen, Nikita Moriakov, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Breast Cancer Research : BCR|November 14, 2023
PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learningWitali Aswolinskiy, Enrico Munari, Hugo M Horlings, et al.
British Journal of Cancer|August 19, 2021
Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breastMaartje van Seijen, Esther H Lips, Liping Fu, et al.
NPJ Breast Cancer|May 6, 2026
Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoringS Doyle, M A Oerlemans, J Brunekreef, et al.
British Journal of Cancer|October 24, 2013
Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancerL S Rigter, C E Loo, S C Linn, et al.
Immuno-Oncology Technology|September 10, 2025
Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stagesN A M Bakker, H Garner, V C M Geurts, et al.
The Journal of Pathology|May 29, 2008
High frequency of copy-neutral LOH in MUTYH-associated polyposis carcinomasA Middeldorp, M van Puijenbroek, M Nielsen, et al.
Radiology|November 18, 2025
Cross-National Radiomics Validation Using Mammography to Predict Occult Invasion in Ductal Carcinoma in SituRui Hou, Lars J Grimm, Jeffrey R Marks, et al.
Breast Cancer Research : BCR|June 19, 2023
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancerM C Liefaard, A van der Voort, M S van Ramshorst, et al.
The American Journal of Surgical Pathology|June 18, 2019
Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCISLindy L Visser, Lotte E Elshof, Koen Van de Vijver, et al.
British Journal of Cancer|April 5, 2025
Development of radiomics-based models on mammograms with mass lesions to predict prognostically relevant characteristics of invasive breast cancer in a screening cohortJim Peters, Merle M van Leeuwen, Nikita Moriakov, et al.
Pageof 13